FR3051196B1 - PARTICLE FOR ENCAPSIDATION OF A GENOME ENGINEERING SYSTEM - Google Patents

PARTICLE FOR ENCAPSIDATION OF A GENOME ENGINEERING SYSTEM Download PDF

Info

Publication number
FR3051196B1
FR3051196B1 FR1654332A FR1654332A FR3051196B1 FR 3051196 B1 FR3051196 B1 FR 3051196B1 FR 1654332 A FR1654332 A FR 1654332A FR 1654332 A FR1654332 A FR 1654332A FR 3051196 B1 FR3051196 B1 FR 3051196B1
Authority
FR
France
Prior art keywords
encapsidation
particle
viral rnas
engineering system
genome engineering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1654332A
Other languages
French (fr)
Other versions
FR3051196A1 (en
Inventor
Pascale Bouille
Regis Gayon
Lucille Lamouroux
Alexandra Iche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VECTALYS
Original Assignee
VECTALYS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1654332A priority Critical patent/FR3051196B1/en
Application filed by VECTALYS filed Critical VECTALYS
Priority to CA3024376A priority patent/CA3024376A1/en
Priority to JP2018559362A priority patent/JP6982001B2/en
Priority to AU2017263137A priority patent/AU2017263137B2/en
Priority to PT177308418T priority patent/PT3455239T/en
Priority to US16/301,317 priority patent/US10870865B2/en
Priority to ES17730841T priority patent/ES2886919T3/en
Priority to EP17730841.8A priority patent/EP3455239B1/en
Priority to DK17730841.8T priority patent/DK3455239T3/en
Priority to SG11201810015YA priority patent/SG11201810015YA/en
Priority to CN201780043702.XA priority patent/CN109415415A/en
Priority to PCT/FR2017/051164 priority patent/WO2017194902A2/en
Publication of FR3051196A1 publication Critical patent/FR3051196A1/en
Priority to IL262941A priority patent/IL262941B/en
Application granted granted Critical
Publication of FR3051196B1 publication Critical patent/FR3051196B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention se rapporte à une particule rétrovirale comportant une protéine issue de la polyprotéine Gag, une protéine d'enveloppe, optionnellement une intégrase et au moins deux ARN non viraux encapsidés, les ARN non viraux encapsidés comportant chacun une séquence d'ARN d'intérêt liée à une séquence d'encapsidation, chaque séquence d'encapsidation étant reconnue par un domaine de liaison introduit dans la protéine issue de la polyprotéine Gag et/ou dans l'intégrase, et l'une au moins dédites séquences d'intérêt des ARN non viraux encapsidés comporte une partie codant pour une nucléase.The present invention relates to a retroviral particle comprising a protein derived from the Gag polyprotein, an envelope protein, optionally an integrase and at least two encapsidated non-viral RNAs, the encapsidated non-viral RNAs each comprising an RNA sequence of interest linked to an encapsidation sequence, each encapsidation sequence being recognized by a binding domain introduced into the protein derived from the polyprotein Gag and/or into the integrase, and at least one of said sequences of interest from Encapsidated non-viral RNAs contain a part coding for a nuclease.

FR1654332A 2016-05-13 2016-05-13 PARTICLE FOR ENCAPSIDATION OF A GENOME ENGINEERING SYSTEM Active FR3051196B1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR1654332A FR3051196B1 (en) 2016-05-13 2016-05-13 PARTICLE FOR ENCAPSIDATION OF A GENOME ENGINEERING SYSTEM
CN201780043702.XA CN109415415A (en) 2016-05-13 2017-05-12 Particle for capsidation genome project system
AU2017263137A AU2017263137B2 (en) 2016-05-13 2017-05-12 Particle for the encapsidation of a genome engineering system
PT177308418T PT3455239T (en) 2016-05-13 2017-05-12 Particle for the encapsidation of a genome engineering system
US16/301,317 US10870865B2 (en) 2016-05-13 2017-05-12 Particle for the encapsidation of a genome engineering system
ES17730841T ES2886919T3 (en) 2016-05-13 2017-05-12 Particle for the encapsidation of a genome engineering system
CA3024376A CA3024376A1 (en) 2016-05-13 2017-05-12 Particle for the encapsidation of a genome engineering system
DK17730841.8T DK3455239T3 (en) 2016-05-13 2017-05-12 Particle for encapsulation of a genomic engineering system
SG11201810015YA SG11201810015YA (en) 2016-05-13 2017-05-12 Particle for the encapsidation of a genome engineering system
JP2018559362A JP6982001B2 (en) 2016-05-13 2017-05-12 Particles for capsid formation in genomic engineering systems
PCT/FR2017/051164 WO2017194902A2 (en) 2016-05-13 2017-05-12 Particle for the encapsidation of a genome engineering system
EP17730841.8A EP3455239B1 (en) 2016-05-13 2017-05-12 Particle for the encapsidation of a genome engineering system
IL262941A IL262941B (en) 2016-05-13 2018-11-12 Particle for the encapsidation of a genome engineering system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1654332A FR3051196B1 (en) 2016-05-13 2016-05-13 PARTICLE FOR ENCAPSIDATION OF A GENOME ENGINEERING SYSTEM

Publications (2)

Publication Number Publication Date
FR3051196A1 FR3051196A1 (en) 2017-11-17
FR3051196B1 true FR3051196B1 (en) 2023-05-12

Family

ID=57583127

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1654332A Active FR3051196B1 (en) 2016-05-13 2016-05-13 PARTICLE FOR ENCAPSIDATION OF A GENOME ENGINEERING SYSTEM

Country Status (1)

Country Link
FR (1) FR3051196B1 (en)

Also Published As

Publication number Publication date
FR3051196A1 (en) 2017-11-17

Similar Documents

Publication Publication Date Title
CY1118018T1 (en) ANTI-C5 ANTIBODIES THAT HAVE IMPROVED PHARMACEUTICAL
CY1124518T1 (en) TRIMER STABILIZING HIV ENVELOPE PROTEIN MUTATIONS
PH12018500657A1 (en) Optimized variants of anti-vegf antibodies
MX2022011309A (en) T cell receptors.
AU2017248121A1 (en) T cell receptors
MX2022006652A (en) Modified capsid proteins for enhanced delivery of parvovirus vectors.
BR112017007202A2 (en) t cell receptors
EA202090562A1 (en) GPCR BINDING PROTEINS AND THEIR SYNTHESIS
EA201792184A1 (en) ANTIBODIES DIRECTED AGAINST T-CELL IMMUNOGLOBULIN AND MUTIN PROTEIN 3 (TIM-3)
MA40662B1 (en) Antibodies against tigit
BR112018011975A2 (en) compositions useful in the treatment of spinal muscular atrophy
EA202091130A1 (en) LYOPHILIZED PREPARATION OF MONOCLONAL ANTIBODY TO TRANSTYRETIN
GEP20237457B (en) Nucleotide hemi-sulfate salt for treatment of hepatitis c virus
MX2019004784A (en) Adeno-associated virus purification methods.
WO2017194902A3 (en) Particle for the encapsidation of a genome engineering system
PH12021550244A1 (en) Anti-btla antibody
EA202091350A1 (en) BINDING MOLECULES SPECIFICALLY BINDING TO TAU PROTEIN
EA201792405A1 (en) DETECTION OF TARGET NUCLEIC ACID AND ITS OPTIONS
EA201992281A1 (en) BINDING MOLECULES SPECIFICALLY BINDING TO TAU PROTEIN
PH12016501444A1 (en) Antibodies against f glycoprotein of hendra and nipah viruses
EA201990884A1 (en) ANTI-C1s ANTIBODIES AND WAYS OF THEIR APPLICATION
EA202192376A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF LAMINOPATHY
CR20210094A (en) Antibodies that bind zika virus envelope protein and uses thereof
CL2017003309A1 (en) Methods of purification and / or viral inactivation
EA201890543A1 (en) METHODS AND MATERIALS FOR GALGT2 GENE THERAPY

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20171117

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9